All In Biotech

Drug Trial Radar · NCT07601646

A Single-Arm, Dose Escalation of an Intraurethral Alprostadil Paste for Erectile Dysfunction

Phase 2 Clinical Trial of ST-04 Intraurethral Paste for Erectile Dysfunction

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

83

Planned (sponsor's estimate)

Start

May 2026

Primary completion

Apr 2027

Study completion May 2027

Sponsor

Lead sponsor
Ryan Flannigan, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 21 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single arm dose escalation trial of a mucoadhesive intraurethral polymer suspension of alprostadil (ST-04) and will investigate the efficacy of 3 dose levels of ST-04 in adult males with a clinical diagnosis of Erectile Dysfunction (ED). This study aims to determine if ST-04, with or without sildenafil, will improve erectile function (EF) compared to baseline. Participants in this study will receive ST-04, a new formulation containing the vasodilator, alprostadil which is known to be an effective drug in treating erectile dysfunction. ST-04 will be dispersed along the urethra, forming a hydrogel which adheres to the lining of the urethra with the goal of penile tumescence and erection. Participants may receive up to 3 dose level escalations of ST-04 over a 12-week period, for a total of up to 11 administrations of ST-04. Dose escalation may also be done with and without sildenafil.

Conditions

  • Erectile Dysfunction (ED)
  • Erectile Dysfunctions
  • Erectile Function

Interventions

  • ST-04Drug

    ST-04 consists of an alprostadil polymer suspension designed for intraurethral application

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in the Erectile Function Domain of the IIEF QuestionnaireTime frame: From baseline to 1 month after start of the last dose level (Week 4, 8, 12 respectively)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vancouver Prostate Centre

    Vancouver, British Columbia, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.